Interaction of anti-tuberculosis preparations with drugs used in COVID-19

Abstract

The COVID-19 pandemic has raised new global health issues, including overlapping SARS CoV-2 infection with tuberculosis, HIV/AIDS, marked by high morbidity and mortality. The treatment of these infections has raised from the outset the efficacy and safety assessment of combining antituberculosis drugs and those used in the treatment of COVID-19. Drug interactions of antituberculosis preparations with antiretrovirals, anti-inflammatory, antibacterial, although partly known, require new approaches in terms of the peculiarities of the evolution of SARS CoV-2 infection, the time of co-infection (association) with COVID-19 and/or tuberculosis, antituberculosis preparations included in treatment regimens